Healthcare · NSE: SUNPHARMA
Intrynsic's multi-model valuation estimates Sun Pharmaceutical Industries Limited's fair value at ₹1,463 per share (range ₹895–₹1,487) against a market price of ₹1,941 - a gap of -24.6% (updated 24 July 2026). This is an estimated fair value based on stated assumptions, not investment advice.
Market price
₹1,941
close of 24 Jul 2026
Est. fair value
₹1,463
₹895–₹1,487
Gap
-24.6%
price vs estimate
Trading ~25% above our estimated fair-value range. Assumptions and per-model workings are below.
Sun Pharma is India's largest drugmaker, selling generics at home and specialty medicines in the US. Its speciality dermatology and eye-care brands earn higher margins than commodity generics.
Healthcare · Healthcare Services
Over the last 3 years, revenue grew 10.0%/yr and profit grew 10.6%/yr.
Every ₹100 of shareholder money earned ₹13.8 in profit last year, vs a sector median of 10.5%.
It holds more cash than debt.
The market price is above our estimated fair-value range (based on stated assumptions).
About ₹103 of every ₹100 of reported profit turned into free cash (median, last 5 years); operating cash flow was positive in 5 of 5 years.
Intrynsic values Sun Pharmaceutical Industries Limited with 3 independent models and blends them into one estimated fair-value range. Every number below is an estimate based on the stated assumptions - change the assumptions and the estimate changes.
| Model | Estimated value | vs price | Weight |
|---|---|---|---|
| DCFFuture Cash Flows Method | ₹895 | -54% | - |
| EV/EBITDAIndustry Comparison Method | ₹1,463 | -25% | - |
| P/E MultipleEarnings Multiple Method | ₹1,487 | -23% | - |
Reverse DCF: today's market price implies the company must grow free cash flow about 33.3% a year for the next decade - versus 10.9% historical revenue growth.
| Revenue | ₹58,462 Cr | |
| Net profit | ₹11,509 Cr | |
| EPS | ₹47.84 | |
| Free cash flow | ₹8,810 Cr | |
| ROE (latest) | 13.8% | |
| Revenue growth (CAGR) | 7.1% | |
| Profit growth (CAGR) | 4.3% |
Intrynsic's multi-model valuation estimates Sun Pharmaceutical Industries Limited's fair value at ₹1,463 per share (range ₹895–₹1,487), last updated 24 July 2026. This is an estimate based on stated assumptions, not investment advice.
Sun Pharmaceutical Industries Limited trades at ₹1,941 against Intrynsic's estimated fair value of ₹1,463 - the market price is 25% above the estimate, i.e. above our estimated fair-value range. Different assumptions produce different estimates; see the model breakdown above.
Sun Pharmaceutical Industries Limited trades at about 40.6 times its latest annual earnings per share.
Sun Pharma is India's largest drugmaker, selling generics at home and specialty medicines in the US. Its speciality dermatology and eye-care brands earn higher margins than commodity generics.
Intrynsic runs 3 valuation models for Sun Pharmaceutical Industries Limited (DCF, EV/EBITDA, P/E Multiple) and blends them into one estimated fair-value range. Every assumption - growth, discount rate, terminal value - is shown openly on this page.
Disclaimer: Intrynsic provides educational and informational analysis only. Fair-value figures are estimates based on stated assumptions - they are not investment advice, research recommendations, or an offer to transact in any security. Intrynsic is not a SEBI-registered investment adviser or research analyst. Markets carry risk; please do your own research or consult a registered adviser before making investment decisions. Prices shown may be delayed end-of-day values. Terms · Privacy